Tim Seymour, portfolio manager of the $CNBS Amplify Seymour Cannabis ETF (NYSE: CNBS), is renowned for recognizing the potential of the cannabis sector early on.
Femasys focuses on innovative women's healthcare solutions. Their FemBloc product, a non-surgical permanent birth control, is in late-stage development, aiming for a $20 billion market.
Petros Pharmaceuticals specializes in men's health therapeutics. President Fady Boctor discusses the company's strategy to make key prescription medications. Petros is poised to expand within the $66.5 billion Rx-to-OTC market projected by 2033.
Financial analyst and investor Keith Gill earned a lasting reputation by posting his analysis of GameStop (GME:NYSE) stock on the subreddit r/wallstreetbets under the username DeepFuckingValue (DFV) and as RoaringKitty on X and YouTube.
Curaleaf International (OTC: CURLF), a leading cannabis company, is expanding its footprint across the UK, Germany and Poland. This strategic expansion is not only about entering new markets but also about outpricing the illegal cannabis trade. What drives their decision to enter specific markets?